Computational design of targeted inhibitors of polo-like kinase 1 (plk1)

Area of Science:

• Medicinal Chemistry
• Computational Drug Design
• Cancer Biology

Background:

• Polo-like kinase 1 (Plk1) is frequently overexpressed in various cancers and plays a critical role in cell cycle regulation.
• Targeting Plk1 is a promising strategy for cancer treatment, but developing specific inhibitors is challenging due to conserved ATP-binding sites across kinases.
• Plk1 possesses a unique polo-box domain (PBD) absent in other kinases, offering a potential target for selective inhibition.

Purpose of the Study:

• To computationally design novel small molecule inhibitors targeting Plk1.
• To leverage the unique Plk1 polo-box domain (PBD) for achieving kinase selectivity.
• To identify drug-like molecules with potential therapeutic applications against Plk1-overexpressing cancers.

Main Methods:

• Identification of common structural features from known Plk1 ligands.
• Design of small molecules based on identified features, focusing on the PBD.
• In silico evaluation of drug likeness and toxicity, followed by molecular docking studies.

Main Results:

• Several designed molecules demonstrated stable binding complexes with Plk1 and LYN kinases.
• One molecule exhibited exclusive binding to the Plk1 polo-box domain (PBD).
• Selected molecules showed favorable drug likeness and no predicted toxicities.

Conclusions:

• Computational design targeting the Plk1 PBD can yield selective kinase inhibitors.
• The identified molecules represent potential leads for developing novel anti-cancer therapeutics.
• Further investigation into these compounds could lead to new treatments for cancers with elevated Plk1 expression.